Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03875573
Title Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer: (Neo-CheckRay)
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Jules Bordet Institute

Her2-receptor negative breast cancer



Durvalumab + Oleclumab

Age Groups: adult | senior
Covered Countries FRA | BEL

No variant requirements are available.